Acute cardiometabole risico’s tijdens de behandeling met haloperidol bij ouderen.

Acute cardiometabolic risks during treatment with haloperidol in elderly patients.

Status

Active, not recruiting

Phases

Unknown

Study type

Observational

Source

NL-OMON

Registry ID

NL-OMON21267

Enrollment

128

Registered

2012-10-25

Start date

2012-12-01

Completion date

Unknown

Last updated

2024-02-28

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

ouderen, delier, antipsychotica elderly, delirium, antipsychotics

Interventions

None listed

Eligibility

Inclusion criteria

Inclusion criteria: 1. Age 70 years and older admitted for hip fracture or other fall-related fractures; 2. Inclusion within 72 hours after admission; 3. 90 days of medication history available.

Exclusion criteria

Exclusion criteria: 1. Use of an antipsychotic agent within 90 days before admission; 2. Start or dose change in of any anticoagulants, Qtc prolongation drugs, antidiabetic drugs, antihypertensive drugs or cholesterol lowering drugs; 3. Terminal illness.

Design outcomes

Primary

Measure	Time frame
1. QTc- prolongation measured with holter ECG; 2. Serum NT-proBNP, glucose, triglycerides; 3. Closure time.	—

Secondary

Measure	Time frame
1. QTc- prolongation measured with ECG; 2. Serum concentration haloperidol; 3. DDD; 4. Total antipsychotic expose; 5. DNA profile.	—

Contacts

Public ContactK. Keulen, van

Tergooiziekenhuisen Postbus 10016

kvankeulen@tergooiziekenhuizen.nl-

Outcome results